Nivolumab for pediatric malignant peritoneal mesothelioma
Pediatr Blood Cancer
.
2023 Feb;70(2):e29892.
doi: 10.1002/pbc.29892.
Epub 2022 Jul 19.
Authors
Melek Yaman Ortaköylü
1
,
Sonay İncesoy Özdemir
1
,
Handan Dinçaslan
1
,
Nurdan Taçyıldız
1
,
Ali Ekrem Ünal
2
,
Çiğdem Soydal
3
,
Ömer Suat Fitöz
4
,
Emel Ünal
1
Affiliations
1
Division of Pediatric Oncology, Department of Pediatrics, Ankara University, Ankara, Turkey.
2
Department of General Surgery, Ankara University, Ankara, Turkey.
3
Department of Nuclear Medicine, Ankara University, Ankara, Turkey.
4
Division of Pediatric Radiology, Radiology Department, Ankara University, Ankara, Turkey.
PMID:
35851543
DOI:
10.1002/pbc.29892
No abstract available
Publication types
Letter
MeSH terms
Child
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / pathology
Mesothelioma* / drug therapy
Mesothelioma* / pathology
Mesothelioma, Malignant* / drug therapy
Nivolumab / therapeutic use
Substances
Nivolumab